




Burden of Illness

NAFLD/NASH


September 2019

NAFLD & NASH Overview¹





Global Prevalence of NAFLD & NASH¹



- Approximately one-quarter of the European population and 1 in 3 of the USA population is affected by NAFLD
- The average prevalence of NAFLD is 23.71% in Europe, varying from 5 - 44% in different countries

 The pooled NASH prevalence in Europe among patients with NAFLD, with an indication for biopsy, was 69.25%

U.S. Prevalence of NAFLD & NASH¹






An estimated **64 million** individuals in the U.S are affected by NAFLD with a reported 21% of NAFLD patients having NASH



NASH is therefore estimated to be prevalent in 12% of the population²



Patients with NASH are likely to have other comorbidities, such as:



U.S. Incidence and Economic Burden of NAFLD and NASH¹



NAFLD¹

The annual burden associated with NAFLD is **\$103 billion**



NAFLD costs \$1,613 per patient

The mean yearly inflation-adjusted charges of Medicare patients with NAFLD from the outpatient setting increased from $$2,624 \pm 3,308$ in 2005 to $$3,608 \pm 5,132$ in 2010

The expected 10-year burden of NAFLD could increase to an estimated **\$1.005 trillion** in the U.S

S

The lifetime cost burden of all NASH is estimated to be **\$859.3** billion

NASH²

8.6 million individuals in the U.S.

are estimated to be affected by

NASH



The projections of cost for each age-specific NASH cohort suggests an estimated **350%** increase in the next five years



5.5 million prevalent adult cases of NASH and **4.5 million** new incident adult cases are predicted in the U.S

1.Younossi, Z., Anstee, Q., Marietti, M., Hardy, T., Henry, L., Eslam, M., George, J. and Bugianesi, E. (2017). Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. *Nature Reviews Gastroenterology & Hepatology*, 15(1), pp.11-20. 2. Natap.org. (2018). *Burden of Illness Economic Model for Patientswith Non-alcoholic Steatohepatitis (NASH) in the United States*. [online] Available at: http://www.natap.org/2017/HCV/121917_01.htm [Accessed 28 Feb. 2018].

NASH Risk Factors¹



Genetic Factors


 Evidence from familial aggregation and twin studies have shown a heritable component to NAFLD

Environmental Factors

- The most relevant environmental factors are dietary habits:
 - Alcohol consumption and the presence of obesity act together to increase the risk of liver disease morbidity and mortality
 - Eating processed foods and/or foods with a high content of fat, salt, and sugar or corn syrup

NASH Care Delivery Gaps






NAFLD Patient Costs




Median Cumulative Healthcare Costs 5 Years After Diagnosis



NAFLD Patient Costs




Median Annual Healthcare Costs After Diagnosis (1 and 5 year)




NAFLD Utilization Rates






NAFLD Costs





NASH Patient Flow Volume





On average, the NAFLD Medicare Advantage patient visits 4.5 times per year and the NAFLD commercial insurance individual visits 3 times

NAFLD/NASH Pipeline Drugs



Allergan	Cer	nicriviroc	
Genfit SA	Ela	fibranor	
Intercept	Ocaliva (obeticholic acid)		
Gilead	Se GS-0976, GS-9674	onsertib	
Boehringer Ingelheim Bristol Myers	BI 1467335 (PXS-4728a)		
Squibb Galmed	BMS-986036 Aramchol		
Novartis	Tropifezor (LJN-452), LMB763		
Novo Nordisk	Liraglutide (Victoza)		
Pfizer	PF-05221304, PF-06835919 PF-06865571, PF-06882961		
Merck	MK-4074		
	Phase 1	Phase 2	Phase 3